Yüklüyor......
Abemaciclib Improves Disease‐Free Survival in High‐Risk HR+/HER2– Early Breast Cancer
Abemaciclib is the first CDK 4/6 inhibitor to show a significant clinical benefit when added to adjuvant endocrine therapy in patients with high‐risk, node‐positive, HR‐positive, HER2‐negative, early‐stage breast cancer, according to findings from the phase III monarchE trial.
Kaydedildi:
| Yayımlandı: | Oncologist |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley & Sons, Inc.
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7869338/ https://ncbi.nlm.nih.gov/pubmed/33399254 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13665 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|